Search

everythinglearnresearchcommunity

for

Search:↓

A user warns against buying the Koreabeautics V2 microneedling pen, claiming it's marketed through fake success stories and is overpriced. Another user shares their experience, acknowledging the pen's quality but agreeing it's too expensive and reliant on frequent needle head replacements.

Breezula's phase 3 results are expected in July or August, with commercialization possibly in two years. There are concerns about delays and effectiveness, and the cost may be high.

Be cautious when sourcing PP405 or its analogs from third-party suppliers due to potential safety risks and lack of regulatory approval. The conversation highlights concerns about counterfeit products and the absence of reliable testing, making it risky to use such treatments.

The user's consideration of taking finasteride as a short-term treatment, while awaiting advances in medical technology such as Pyrilutamide and GT20029; other users' experiences with Finasteride, including potential side effects.

Verteporfin may improve hair transplant outcomes and reduce scarring, potentially allowing patients to avoid finasteride. Dr. Barghouthi seeks collaborations, volunteers, and financial support for research on verteporfin.org.

The conversation is about whether castor oil can be effectively used alone after microneedling without a penetration enhancer like DMSO or ethanol. The user believes microneedling-induced wounds might be enough for absorption.

Avoid clinics that push for more grafts than necessary, as it can lead to unnecessary costs and damage to the donor area. Trust reputable clinics and be cautious of those using celebrity endorsements or offering suspiciously low prices.

Capilia Longa and Scandinavian Biolabs are discussed, with skepticism about their effectiveness and value. The conversation suggests avoiding these products due to high cost and perceived lack of results.

Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.

Verteporfin is being explored for its potential to improve hair transplant outcomes by reducing scarring and increasing donor hair follicles. There is skepticism about the results, with some claiming misleading presentation of evidence.

A user asks about experiences with Minichek F 5% with Procapil, specifically its drying time. Responses discuss the effectiveness and drying time of the treatment.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Dr. Bloxham's trial is testing verteporfin on hair transplant patients to see if it can improve hair regrowth in treated areas. People are discussing the potential for follicle regeneration, expected results timeline, and concerns about side effects like cancer.

The conversation discusses the effectiveness of Dutasteride for hair loss, with some users reporting it works better than Finasteride and sharing positive experiences, while others are skeptical due to negative anecdotes. Specific treatments mentioned include Dutasteride and Finasteride.

The conversation discusses experimenting with microneedling for hair loss, specifically addressing non-responsiveness and the use of topical treatments like dutasteride, minoxidil, and tretinoin. The user seeks advice on effective frequency and depth combinations for better results.

The conversation discusses the less impressive results of Pyrilutamide (kx-836) in phase 3 compared to phase 2, with a suggestion that a longer study might show more significant results. One user reports personal success with Pyrilutamide, experiencing no further hair loss and gradual regrowth.

Microneedling at .25 depth may not be as effective as other depths for hair loss treatment. Minoxidil and tretinoin are used, but DHT blockers are also recommended for better results.

PRP treatments have been effective for the user, with a new recommendation of using a high-quality plasma kit once a year. The user seeks experiences with this specific PRP approach.

The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.

OP is considering dutasteride mesotherapy for hair loss after experiencing side effects from finasteride. A user shared their experience, stating that the treatment was ineffective and costly.

A user had a failed hair transplant with 2800 FUE grafts at a clinic in Turkey, where finasteride was used, and the procedure was poorly executed by technicians rather than the main surgeon. The user later sought repair from a more experienced doctor, highlighting issues with large clinics that handle multiple patients daily.

The conversation discusses the potential cost of hair transplants if verteporfin allows for an unlimited donor area, suggesting that prices could vary based on the number of grafts needed. The user speculates that costs could be calculated per graft or a set amount for a specific number of grafts.

Users discuss finding reliable sources for RU58841, focusing on lab tests, batch consistency, and community reputation. Some mention using alternatives like pyrilutamide.

PP405 is criticized for overhyped claims and cherry-picked data, with doubts about its effectiveness compared to minoxidil and finasteride. Many users express skepticism, emphasizing the need for more comprehensive trial results.

Pyrilutamide and RU58841 are androgen receptor antagonists that block receptors without significantly reducing testosterone or DHT levels. Any indirect effect on androgen levels is likely negligible.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation discusses the effectiveness of finasteride and dutasteride for hair loss, with some users finding no improvement and experiencing side effects. It also mentions the use of RU58841 and topical minoxidil, highlighting that hair sensitivity to DHT varies among individuals.

The conversation discusses the variability in effectiveness of medications, including finasteride, and questions whether different manufacturers impact results. The user suggests sharing successful brands to help others identify effective options.

Doctors are testing verteporfin topically for healing and potential regeneration after transplants. The user is asking how it is formulated for topical use, such as if it's mixed with a carrier gel.